Stryker Corporation(SYK) Stock Research - Grey Stern Research
Loading...

Stryker Corporation (SYK) Stock Analysis

$390.97 (0.34%)

SYK Financial Performance


Use the table below to view Stryker Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $390.97 -
52 Week Low $285.79 -
52 Week High $398.20 -
Market Cap $149.0 Billion 2/9
Gross Margin 64% 6/9
Profit Margin 15% 2/9
EBITDA margin 20% 3/9
Q3 - 2024 Revenue $5.5 Billion 3/9
Q3 - 2024 Earnings $834.0 Million 3/9
Q3 - 2024 Free Cash Flow $1.3 Million 1/9
Trailing 4 Quarters Revenue $22.0 Billion 3/9
Trailing 4 Quarters Earnings $3.6 Billion 3/9
Quarterly Earnings Growth 21% 4/9
Annual Earnings Growth 24% 5/9
Quarterly Revenue Growth 12% 2/9
Annual Revenue Growth 10% 2/9
Cash On Hand $3.9 Billion 1/9
Short Term Debt $13.3 Billion 1/9
Long Term Debt $13.3 Billion 2/9

Stryker Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Stryker Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 41.52 4/9
PS 6.78 3/9
PB 4.12 4/9
PC 38.71 6/9
Liabilities to Equity 0.17 8/9
ROA 0.08 3/9
ROE 0.08 5/9
Current Ratio 5.72 1/9
Quick Ratio 0.60 2/9
Long Term Debt to Equity 0.30 7/9
Debt to Equity 0.30 7/9
Burn Rate 1.27 5/9
Cash to Cap 0.03 3/9
CCR 1.56 1/9
EV to EBITDA 146.10 3/9
EV to Revenue 7.21 3/9

Company Details

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

CEO: Mr. Kevin Lobo

Website: https://www.stryker.com

Address: 2825 Airview Blvd Portage, MICHIGAN

Exchange: New York Stock Exchange

Industry: Medical Devices

Stryker Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Stryker Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Boston Scientific Corporation BSX $133.3 Billion
Abbott Laboratories ABT $201.7 Billion
Medtronic plc MDT $109.9 Billion
Zimmer Biomet Holdings, Inc. ZBH $22.0 Billion
DexCom, Inc. DXCM $31.6 Billion
Edwards Lifesciences Corporation EW $41.4 Billion
STERIS plc STE $21.4 Billion
ZimVie Inc. ZIMV $407.1 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
SYK Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 5.5 Billion $834.0 Million
Q2 2024 $ 5.4 Billion $825.0 Million
Q1 2024 $ 5.2 Billion $788.0 Million
Q4 2023 $ 5.8 Billion $1.1 Billion
Q3 2023 $ 4.9 Billion $692.0 Million
Q2 2023 $ 5.0 Billion $738.0 Million
Q1 2023 $ 4.8 Billion $592.0 Million
Q4 2022 $ 5.2 Billion $563.0 Million

View All

SYK Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $3.9 Billion $43.8 Billion $13.3 Billion $43.8 Billion
Q2 2024 $1.9 Billion $39.1 Billion $12.7 Billion $19.8 Billion
Q1 2024 $2.3 Billion $39.4 Billion $10.8 Billion $19.2 Billion
Q4 2023 $2.9 Billion $39.9 Billion $10.9 Billion $39.9 Billion
Q3 2023 $1.9 Billion $38.0 Billion $10.4 Billion $17.9 Billion
Q2 2023 $1.4 Billion $37.4 Billion $11.1 Billion $17.4 Billion
Q1 2023 $1.7 Billion $36.8 Billion $11.9 Billion $16.9 Billion
Q4 2022 $1.8 Billion $36.9 Billion $13.0 Billion $16.6 Billion

View All

SYK Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $1.3 Billion -$170.0 Million $2.0 Billion
Q2 2024 $481.0 Million -$152.0 Million -$456.0 Million
Q1 2024 $37.0 Million -$167.0 Million -$641.0 Million
Q4 2023 $1.4 Billion -$145.0 Million $1.1 Billion
Q3 2023 $902.0 Million -$148.0 Million $459.0 Million
Q2 2023 $536.0 Million -$152.0 Million -$270.0 Million
Q1 2023 $315.0 Million -$130.0 Million -$2.0 Billion
Q4 2022 $815.0 Million -$188.0 Million $424.0 Million

View All